Sonolisib

Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ) ) . Antitumor activity[1][2].

Product Specifications

CAS Number

[502632-66-8]

Product Name Alternative

PX-866

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sonolisib.html

Purity

99.00

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C(/C(C(O[C@@H]4COC)=O)=C\N(CC=C)CC=C)=C1O

Molecular Formula

C29H35NO8

Molecular Weight

525.59

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Ihle NT, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growthfactor receptor inhibitor ZD1839 in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther. 2005 Sep;4 (9) :1349-57.|[2]Bowles DW, et al. A Randomized, Phase II Trial of C225 With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clin Colorectal Cancer. 2016 Dec;15 (4) :337-344.e2.|[3]Sonolisib